English
English
English
Cancer medicines are set to become more affordable from November 9 following major price revisions announced by the NPPA. (Img: Pinterest)
New Delhi: Come November 9, cancer medicines are set to become considerably more affordable, as steep price cuts promise much-needed relief to patients battling not just a life-threatening disease but also its crushing financial burden. The National Pharmaceutical Pricing Authority (NPPA) has reduced the maximum retail prices of 543 formulations across 137 non-scheduled cancer medicines by up to 93.3%, offering significant financial relief to patients and their families.
The price reductions are expected to ease the cost of several cancer drugs, with some formulations witnessing exceptionally steep cuts. The move comes amid growing concerns over the financial burden of cancer care in India, where the cost of medicines, diagnostic procedures, hospitalisation and other treatment-related expenses can place considerable pressure on patients and their families. The revised prices are scheduled to come into effect on November 9, making the announcement particularly significant for patients who depend on the affected formulations as part of their treatment.
Among the most significant reductions is that of Samtepa, a 100 mg vial of thiotepa. Its maximum retail price has been reduced from Rs 80,071.86 to Rs 7,150.33, translating into a cut of Rs 72,921.53, or approximately 91.1%.
Another substantial reduction has been announced for Palbopro, a pack of 21 capsules of palbociclib 125 mg. Its price has been brought down from Rs 40,421.33 to Rs 2,720, marking a reduction of approximately 93.3%.
These reductions could substantially lower medicine bills for patients prescribed the affected brands and formulations. Actual savings will depend on the prescribed medicine, dosage, duration of treatment and applicable revised retail price.
The price revisions extend to several other cancer medicines used in oncology treatment. The maximum retail price of Hertumab, a pertuzumab vial, has been reduced from Rs 94,951 to Rs 30,593. Lupiher 420 mg has seen its price fall from Rs 83,520 to Rs 37,358.35.
The revised prices also cover bevacizumab formulations. The price of a 400 mg vial of Ivzumab has been reduced from Rs 69,852.12 to Rs 13,512. Bevacizab 400 mg has seen a reduction from Rs 65,205.09 to Rs 8,956.75, while Cizumab 400 mg has been repriced from Rs 57,816 to Rs 10,211.
Other affected formulations include Brcaone, an olaparib 150 mg product, whose price has been reduced from Rs 46,364.05 to Rs 11,573.68. Peg L-Aparagin has seen its price fall from Rs 41,845.97 to Rs 7,766.85.
The revised maximum retail price of Abirat 250 mg, sold in a bottle containing 120 tablets, has been reduced from Rs 36,088.81 to Rs 4,064.48. Patients and caregivers should verify the revised price of their specific formulation and pack size with a pharmacist or healthcare provider before purchasing their medicines.
The price revisions are estimated to generate annual savings of Rs 2,500 crore to Rs 3,500 crore for patients, according to figures reported in connection with the decision. The NPPA has indicated that India's anti-cancer drug market is worth approximately Rs 12,500 crore.
Of this, 63 scheduled cancer medicines listed under the National List of Essential Medicines (NLEM), 2022, account for around Rs 2,250 crore. The market for non-scheduled cancer medicines is estimated to exceed Rs 10,250 crore.
The latest intervention addresses a substantial segment of the cancer medicine market outside the scheduled-drug category. The actual benefits will depend on patient purchases and the extent to which the affected formulations are used.
While lower medicine prices can ease a major component of treatment expenditure, cancer care involves a wider range of costs. Patients may also face expenses related to surgery, chemotherapy, radiotherapy, diagnostic tests, hospital stays, specialist consultations and supportive care.
The price cuts are an important affordability measure, but their impact on overall household medical spending will vary according to individual treatment plans and circumstances.
The debate over healthcare affordability has also extended to hospital consumables and medical supplies, where concerns have been raised about substantial mark-ups. Questions about medicine pricing, trade margins and the transparency of healthcare charges have attracted wider public and legal scrutiny.
The challenge for policymakers is to make essential treatment more accessible while ensuring that healthcare providers can sustain the infrastructure, technology and specialised clinical services required for cancer care.
Dr Harit Chaturvedi, chief of oncology at Apollo Hospitals, has highlighted the importance of balancing affordability with the costs associated with technology, hospital operations and advanced clinical care.
Senior Advocate Ajay Verma has also discussed the legal basis of medicine price regulation and the need to maintain a balance in pricing policy.
The broader debate centres on how regulatory intervention can improve access to treatment while supporting a sustainable healthcare ecosystem. Price controls, market competition and transparent billing practices remain important considerations.
The revised prices are scheduled to take effect on November 9. Patients taking cancer medicines should check whether their prescribed brand, strength and pack size are covered by the announced revisions.
They should confirm the applicable maximum retail price with a pharmacist or healthcare provider and consult their treating oncologist before making any changes to a prescribed medicine. A lower-priced formulation should not be substituted without appropriate medical guidance.
For patients and families facing the financial strain of cancer treatment, the announced cuts could provide meaningful relief on affected medicines. The extent of that relief will depend on individual prescriptions, treatment requirements and the revised prices applicable to the products they purchase.
